Effectiveness of Dupilumab Treatment in Patients With Type 2 Inflammation: A Real-Life Integrated Experience
Authors:
Open Access
- 1 May 2025
- journal article
- Published by SAGE Publications in Therapeutic Advances in Allergy and Rhinology
- Vol. 16
Abstract
Background: Type 2 inflammation plays a pivotal role in various allergic and inflammatory diseases, including chronic rhinosinusitis, asthma, atopic dermatitis, and eosinophilic esophagitis. Dupilumab is one of the emerging therapeutic targets that modulate the key mediators and cellular players involved in type 2 inflammation, aiming to improve the immune response and the quality of life of the patient. Objective: Here, we describe the experience made on 792 patients enrolled by several specialists of a multidisciplinary team working on inflammatory type 2 diseases. Design: Retrospective study. Methods: Patients were treated with dupilumab according to the prescribed indications and were evaluated by several exams, tests, and questionnaires at baseline (T0) and after 12 (T1), 18 (T2), and 24 (T3) months. Results: Overall, dupilumab exerts beneficial effects as demonstrated both by patients-reported outcomes and by objective assessments. Compared to baseline, all examined efficacy indicators showed an improvement after 12 months, with positive effects sustained through the 2 years of observation. Our results align with several previous trials. Conclusion: Understanding the interconnection between different type 2 inflammatory diseases provides insight into potential avenues for precision medicine approaches and targeted therapies.Keywords
This publication has 36 references indexed in Scilit:
- Type 2 inflammation in asthma — present in most, absent in manyNature Reviews Immunology, 2014
- Interleukin‐4 and interleukin‐13 compromise the sinonasal epithelial barrier and perturb intercellular junction protein expressionInternational Forum of Allergy & Rhinology, 2014
- Dupilumab in Persistent Asthma with Elevated Eosinophil LevelsNew England Journal of Medicine, 2013
- Psychometric validity of the 22‐item Sinonasal Outcome TestClinical Otolaryngology, 2009
- Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studiesBMJ, 2007
- Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialistsJournal of Allergy and Clinical Immunology, 2006
- The eczema area and severity index (EASI): assessment of reliability in atopic dermatitisExperimental Dermatology, 2001
- Quantification for staging sinusitis. The Staging and Therapy Group.1995
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994
- Staging in rhinosinusitus.1993